Written question asked by Lord Kamall (Conservative) on Tuesday, 27 January 2026, in the House of Lords. It was due for an answer on Tuesday, 10 February 2026. It was answered by Baroness Merron (Labour) on Wednesday, 4 February 2026 on behalf of the Department of Health and Social Care.
Kidney Diseases: Testing
- Question
-
To ask His Majesty's Government what assessment they have made of the cost-effectiveness of increasing the uptake of urine albumin-creatine ratio tests so that all patients with chronic kidney disease have an annual test.
- Answer
-
The Department has not made a specific assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing clinical guidance and quality standards. NICE’s guidance on chronic kidney disease includes guidance on the use of annual urine albumin-creatine ratio tests as the preferred method to detect and monitor kidney disease. The guidance is available on NICE’s website.
Secondary information
- Type
- Written question
- Reference
- HL13998
- Session
- 2024-26
- Subjects
- Cost effectiveness Testing Kidney diseases
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-02-04 13:37:12 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13998
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13998
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL13998